Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma | Zendy

Yasushi Rino | Zendy; Norio Yukawa | Zendy; Nobuyuki Wada | Zendy; Makoto Suzuki | Zendy; Hitoshi Murakami | Zendy; Takanobu Yamada | Zendy; Hirotaka Nakayama | Zendy; Naoto Yamamoto | Zendy; Tsutomu Sato | Zendy; Roppei Yamada | Zendy; Takashi Ohshima | Zendy; Munetaka Masuda | Zendy; Toshio Imada | Zendy

Open Access

Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma

Author(s) -

Yasushi Rino,

Norio Yukawa,

Nobuyuki Wada,

Makoto Suzuki,

Hitoshi Murakami,

Takanobu Yamada,

Hirotaka Nakayama,

Naoto Yamamoto,

Tsutomu Sato,

Roppei Yamada,

Takashi Ohshima,

Munetaka Masuda,

Toshio Imada

Publication year - 2008

Publication title -

clinical medicine oncology

Language(s) - English

Resource type - Journals

ISSN - 1177-9314

DOI - 10.4137/cmo.s610

Subject(s) - medicine , leukopenia , regimen , chemotherapy , adverse effect , paclitaxel , cisplatin , toxicity , gastroenterology , cancer , chemotherapy regimen , neutropenia , surgery

We conducted a pilot phase II study to evaluate the efficacy and safety of S-1 as a first-line, S-1 plus cisplatin as a second-line, and weekly paclitaxel as a third-line therapy for advanced gastric cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research